American Society of Hirudotherapy

Drug Regulatory Authority of Pakistan

DRAP · Pakistan · asia pacific

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Pakistan's Drug Regulatory Authority — federal authority over therapeutic goods; leech-specific regulatory pathway has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
asia pacific
Country
Pakistan
Leech status
unregulated
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Drug Regulatory Authority of Pakistan Act, 2012
  • Pakistani national medical-device regulatory framework

Prescriber Requirements

  • PMC (Pakistan Medical Commission)-registered MD prescription required
  • Traditional medicine (Tibb) and complementary medicine practitioner scope under the National Council for Tibb / National Council for Homoeopathy for hirudotherapy not independently verified by ASH

Supply Chain & GMP

DRAP product registration if classified as a medical device; English and Urdu-language labelling.

Import/Export Rules

DRAP import licence plus Department of Plant Protection / animal quarantine clearance for live invertebrates; CITES Appendix II paperwork.

Reimbursement Context

Sehat Sahulat Programme and provincial social health insurance coverage for hirudotherapy not independently verified by ASH.

ASH Editorial Notes

Pakistan has a long-standing Tibb (Unani) traditional medicine tradition with statutory recognition via the National Council for Tibb; whether leech therapy is regulated as a Tibb modality or as a medical device under DRAP has not been independently verified by ASH.

Related Jurisdictions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.